Results 51 to 60 of about 5,445 (182)

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

BMC Nephrology, 2022
Background Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4).
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L. Barnett, Dorothee Oberdhan, Terry Watnick, Stephen Seliger   +7 more
doaj   +1 more source

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

British Journal of Pharmacology, EarlyView.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer, Paraskevi Sotiropoulou, Koussai Bouker, Dennis Svedberg, Rebekkah Hammar, Hester Bange, Per Larsson, André Mateus, Daniel R. Dietrich, Per Artursson   +9 more
wiley   +1 more source

Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan

, 2023
Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of T-cell-mediated liver injury in a small number of patients.
Mosedale, Merrie, Naisbitt, Dean J, Hammond, Sean, Meng, Xiaoli   +3 more
core   +1 more source

Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review

Cancer Treatment and Research Communications
Background: Hyponatremia due to the syndrome of inappropriate antidiuretic hormone (SIADH) occurs in approximately 25 % of patients with small cell lung cancer (SCLC). Tolvaptan has emerged as a promising option to treat SIADH in such patients.
Victoria L. Cammann, Menzi Sheryl, Thomas Fürst, Andreas W. Jehle   +3 more
doaj   +1 more source

Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial

Indian Heart Journal, 2016
Objectives: To assess the efficacy of tolvaptan in acute heart failure with hyponatremia using a randomized double-blinded placebo-controlled study design. Background: Tolvaptan is a selective vasopressin receptor 2 antagonist.
Elangovan Shanmugam, C.R. Madhu Prabhu Doss, Melvin George, Amrita Jena, Muthukumar Rajaram, Balaji Ramaraj, Karthik Anjaneyan, B. Kanagesh   +7 more
doaj   +1 more source

Severe tolvaptan-associated hyperglycemia: a case report

Journal of Medical Case Reports
Background Tolvaptan-associated hyperglycemia has rarely been described in literature. Case presentation A 95-year-old East Asian (Chinese) male patient with hyponatremia started on tolvaptan treatment at a dosage of 15 mg per day.
Huihuan Sun, Ping Yang, Lijuan Chen, Ying Zhang, Shudong Liu, Wenxiu Sun   +5 more
doaj   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

, 2021
(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed.
Atsushi Hosui, Takafumi Tanimoto, Toru Okahara, Kohsaku Ohnishi, Motohiro Hirao, Naoki Hiramatsu, Munehiro Ashida, Takuya Yamada, Yuhhei Wakahara, Yukihiro Kusumoto, Toshio Yamaguchi, Yuka Sueyoshi   +11 more
core   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

Hepatology Research, Volume 56, Issue 6, Page 925-932, June 2026.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano, Taeang Arai, Hidenori Toyoda, Keizo Kato, Joji Tani, Suguru Ogura, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Toshifumi Tada, Akito Nozaki, Atsushi Hiraoka, Kentaro Matsuura, Toru Ishikawa, Naoto Kawabe, Tsunamasa Watanabe, Koichi Takaguchi, Asahiro Morishita, Hironao Okubo, Motoh Iwasa, Hiroki Nishikawa, Yasuhito Tanaka, Masanori Atsukawa   +22 more
wiley   +1 more source

Tolvaptan Improves Refractory Ascites and Overall Survival in Cirrhosis: A Meta-Analysis

Current Internal Medicine Research and Practice Surabaya Journal
Introduction: Refractory ascites is a frequent complication associated with liver cirrhosis. Tolvaptan, a V2-receptor antagonist, has shown effectiveness in improving refractory ascites.
Chetan Kalal, Harshad Joshi, Shankar Zanwar, Madhumita Premkumar   +3 more
doaj   +1 more source